Emerging drugs for sarcopenia: age-related muscle wasting
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Sarcopenia is the term widely used to describe the progressive loss of muscle mass with advancing age. Even before significant muscle wasting becomes apparent, ageing is associated with a slowing of movement and a gradual decline in muscle strength, factors that increase the risk of injury from sudden falls and the reliance of the frail elderly on assistance in accomplishing even basic tasks of independent living. Sarcopenia is recognised as one of the major public health problems now facing industrialised nations, and its effects are expected to place increasing demands on public healthcare systems worldwide. Although the effects of ageing on skeletal muscle are unlikely to be halted or reversed, the underlying mechanisms responsible for these deleterious changes present numerous targets for drug discovery with potential opportunities to attenuate muscle wasting, improve muscle function, and preserve functional independence. Very few drugs have been developed with sarcopenia specifically in mind. However, because many of the effects of ageing on skeletal muscle resemble those indicated in many neuromuscular disorders, drugs that target neurodegenerative diseases may also have important relevance for treating age-related muscle wasting and weakness. This review describes a selection of the emerging drugs that have been developed during the period 1997 - 2004, relevant to sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“12 Growth differentiation factors Myostatin (growth differentiation factor-8, GDF-8), a member of the transforming growth factor (TGF)-β superfamily, is a growth factor that has attracted much attention since it was determined that the absence of myostatin resulted in increased muscle size, known as double muscling in…”
BackgroundStitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Invited Review: Aging and sarcopenia
Doherty, T. J. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00347.2003 · Cited by 1,764 · cited 1×
“1 Neuromuscular mechanisms of age-related changes in muscle structure and function The underlying mechanisms for the changes in skeletal muscle structure and function with advancing age have been described in detail in other reviews [3-18].”
BackgroundRommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583
The healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546
Aging of skeletal muscle: a 12-yr longitudinal study
Frontera, W. R., Hughes, V. A., Fielding, R. A., Fiatarone, M. A., Evans, W. J., & Roubenoff, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1321 · Cited by 1,443
Musarò, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E. R., L Sweeney, H., & Rosenthal, N. (2001) · Nature Genetics · doi:10.1038/84839 · Cited by 1,137
Myostatin, a Negative Regulator of Muscle Growth, Functions by Inhibiting Myoblast Proliferation
Thomas, M., Langley, B., Berry, C., Sharma, M., Kirk, S., Bass, J., & Kambadur, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004356200 · Cited by 1,014 · cited 1×
“Myostatin is a negative regulator of myogenesis, and suppresses myoblast proliferation [160] and myogenic differentiation [161].”
BackgroundRetrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 1×
“Given that chronic delivery of molecules to the central nervous system has proven difficult, Kaspar and colleagues [113] found that adeno-associated virus could be retrogradely transported efficiently from muscle to motor neurons of the spinal cord, showing that IGF-I prolonged life and delayed disease progression, ev…”
BackgroundFunctional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · cited 1×
“These findings support the notion that myostatin inhibitors could provide a therapeutic benefit in conditions where muscle mass is limiting, including sarcopenia [166,169-171].”
BackgroundEffects of Resistance Training on Older Adults
Hunter, G. R., McCarthy, J. P., & Bamman, M. M. (2004) · Sports Medicine · doi:10.2165/00007256-200434050-00005 · Cited by 764 · cited 1×
“Over the last decade or so, considerable evidence has accumulated describing the potential for resistance (strength) exercise training to restore muscle mass and function significantly, even in the frail elderly [2].”
BackgroundSignalling pathways that mediate skeletal muscle hypertrophy and atrophy
Glass, D. J. (2003) · Nature Cell Biology · doi:10.1038/ncb0203-87 · Cited by 694
Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14938 · Cited by 571 · cited 1×
“High serum and muscular levels of myostatin are associated with the cachexia associated with HIVinfected men [162].”
BackgroundExercise comes of age: rationale and recommendations for a geriatric exercise prescription
Singh, M. A. F. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m262 · Cited by 485
Testosterone action on skeletal muscle
Herbst, K. L., & Bhasin, S. (2004) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200405000-00006 · Cited by 457 · cited 1×
“Therapies relating to GH/IGF-I and their relevance for sarcopenia have been described in detail elsewhere [42,43], along with further details on specific studies [71-82].”
BackgroundControl of the size of the human muscle mass
Rennie, M. J., Wackerhage, H., Spangenburg, E. E., & Booth, F. W. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.052102.134444 · Cited by 399 · cited 1×
“Considerable research efforts are focused on the mechanisms regulating skeletal muscle mass (for review, see [58]).”
BackgroundDifferential regulation by exercise of BDNF and NT-3 in rat spinal cord and skeletal muscle
Gómez‐Pinilla, F., Ying, Z., Opazo, P., Roy, R. R., & Edgerton, V. R. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01484.x · Cited by 362
The Neuroendocrinology of Human Puberty Revisited
Grumbach, M. M. (2002) · Hormone Research in Paediatrics · doi:10.1159/000058094 · Cited by 362
Myostatin Knockout in Mice Increases Myogenesis and Decreases Adipogenesis
Lin, J., Arnold, H. B., Della-Fera, M. A., Azain, M. J., Hartzell, D. L., & Baile, C. A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6500 · Cited by 313 · cited 1×
“Experiments in mice showed that blocking myostatin with antibodies [164] and silencing of the myostatin gene resulted in decreased fat content [165].”
BackgroundHasten, D. L., Pak-Loduca, J., Obert, K. A., & Yarasheski, K. E. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.4.e620 · Cited by 294 · cited 1×
“It is not entirely clear whether differences in basal muscle protein turnover explain the age-related loss in muscle mass in humans [35-38].”
BackgroundSarcopenia: Effects on Body Composition and Function
Roubenoff, R. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.11.m1012 · Cited by 282 · cited 1×
“Sarcopenia is the term widely used to describe the slow, but progressive, loss of muscle mass with advancing age [1].”
BackgroundNeural control of aging skeletal muscle
Delbono, O. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00011.x · Cited by 248 · cited 1×
“Claims that neurotrophic factors have relevance for treating neuromuscular disorders including sarcopenia have been described elsewhere [42,43,57].”
BackgroundYarasheski, K. E., Pak-Loduca, J., Hasten, D. L., Obert, K. A., Brown, M. B., & Sinacore, D. R. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.1.e118 · Cited by 226
Vukovich, M. D., Stubbs, N. B., & Bohlken, R. M. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.7.2049 · Cited by 222 · cited 1×
“Furthermore, administration of HMB to older adults involved in resistance training resulted in increased strength and decreased fat mass [175].”
BackgroundCreatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy
Tarnopolsky, M. A., Mahoney, D. J., Vajsar, J., Rodriguez, C., Doherty, T. J., Roy, B. D., & Biggar, D. (2004) · Neurology · doi:10.1212/01.wnl.0000125178.18862.9d · Cited by 216 · cited 1×
“The potential for creatine supplementation to increase lean body mass makes it relevant for application to the treatment of sarcopenia [179], as well as other conditions in which muscle wasting is indicated, including neuromuscular disorders [180-182].”
BackgroundCreatine supplementation improves muscular performance in older men
GOTSHALK, L. A., VOLEK, J. S., STARON, R. S., DENEGAR, C. R., HAGERMAN, F. C., & KRAEMER, W. J. (2002) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200203000-00023 · Cited by 158 · cited 1×
“Supplementation with creatine monohydrate has been advocated for older adults because it has been shown to enhance muscle strength even after only 5 – 7 days’ administration [178].”
Signaling pathways weigh in on decisions to make or break skeletal muscle
Guttridge, D. C. (2004) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/01.mco.0000134364.61406.26 · Cited by 149 · cited 1×
“Interventions that can increase Akt signalling or modulate myostatin and NF-κB activities may prove useful in sarcopenia and other muscle-wasting disorders [59].”
BackgroundPotential benefits of creatine monohydrate supplementation in the elderly
Tarnopolsky, M. A. (2000) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200011000-00013 · Cited by 65 · cited 1×
“The potential for creatine supplementation to increase lean body mass makes it relevant for application to the treatment of sarcopenia [179], as well as other conditions in which muscle wasting is indicated, including neuromuscular disorders [180-182].”
Background
Cited by
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574
“It is hoped that androgenic signaling with these agents can achieve gains in skeletal muscle mass and strength without dose-limiting adverse events.(32) Other compounds under investigation as treatments for sarcopenia include myostatin, vitamin D, angiotensin-converting enzyme inhibitors, eicosapentaenoic acid,(30,31)…”
BackgroundSarcopenia: A Contemporary Health Problem among Older Adult Populations
Papadopoulou, S. (2020) · Nutrients · doi:10.3390/nu12051293 · Cited by 588
Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging
Andersson, D. C., Betzenhauser, M. J., Reiken, S., Meli, A. C., Umanskaya, A., Xie, W., Shiomi, T., Zalk, R., Lacampagne, A., & Marks, A. R. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.05.014 · Cited by 424
Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness
Ryall, J. G., Schertzer, J. D., & Lynch, G. S. (2008) · Biogerontology · doi:10.1007/s10522-008-9131-0 · Cited by 423
“As the number and proportion of older persons in the population continues to escalate, sarcopenia will impact dramatically on quality of life and place ever-increasing demands on public health care (see Lynch 2004a for review).”
BackgroundResultSelf-citationRole of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease
Lynch, G. S., & Ryall, J. G. (2008) · Physiological Reviews · doi:10.1152/physrev.00028.2007 · Cited by 410
Self-citation
Metadata
- Authors
- Lynch, G. S.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa Healthcare
- Published
- 2004-11
- Volume
- 9
- Issue
- 2
- Pages
- 345-361
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2096094625
- Cited by
- 43
- References
- 30
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.